中文

SELLAS (SLS)

Biotech

Close on Nov 17, 2026 (from our latest article): $19.15

Market value
$3.9Bat the Nov 17 close
Cash used, 12 months
$27M12 months to Sep 30, 2026 (10-Q)
Net cash
$135Mat Sep 30, 2026
Worst fall since listing
−100.0%Mar 13, 2008 to Jan 18, 2024; not back to that high (−100.0% now)

About the company

Latest

  • Up 156.4% Move
    SELLAS nearly triples as its leukemia vaccine extends survival

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

Long-term fundamentals

Annual results for SELLAS, FY2010–FY2025, as reported in its 10-K filings.

Revenue and free cash flow

Revenue went from $2M in FY2013 to $1M in FY2022. Free cash flow was positive in 0 of the 6 years shown; FY2016: −$12M. Each year's figures are in the table below. −$60M−$40M−$20M$0$20M ’11 ’13 ’15 ’19 ’21 ’23

Revenue went from $2M in FY2013 to $1M in FY2022.

Free cash flow was positive in 0 of the 6 years shown; FY2016: −$12M.

Margins

Margins are not charted: in FY2022 the operating loss (−$42M) was larger than revenue ($1M). The table has each year's figures.

Diluted share count

The diluted share count rose 1267% from FY2020 to FY2025, to 109M. Each year's figures are in the table below. 0M25M50M75M100M125M ’20’21’22’23’24’25

The diluted share count rose 1267% from FY2020 to FY2025, to 109M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025———−$27M−$28M——
FY2024———−$31M−$35M——
FY2023$0——−$37M−$31M——
FY2022$1M—−4195%−$41M−$24M——
FY2021$8M—−333%−$21M−$26M——
FY2020$2M—−894%−$17M−$10M——
FY2019$0——−$19M−$18M——
FY2018———−$28M−$30M——
FY2017———−$24M−$11M——
FY2016———−$18M−$12M$0.0M−$12M
FY2015———−$64M−$48M$0.5M−$49M
FY2014$9M—−471%−$37M−$43M$3M−$46M
FY2013$2M—−1146%−$77M−$29M$16M−$44M
FY2012$0——−$35M−$21M——
FY2011$0——−$11M−$15M$0.1M−$15M
FY2010———−$12M−$10M$0.1M−$10M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY2025109M$72M—$2M——
FY202461M$14M—$2M——
FY202328M$3M—$2M——
FY202219M$17M—$2M——
FY202115M$21M—$1M——
FY20208.0M$35M—$0.6M——
FY2019—$7M—$0.6M$0—
FY2018—$5M$0$0.4M$0.5M—
FY2017—$2M$11M$3M$0—
FY2016—$6M$7M$0.4M——
FY2015—$1M$5M$2M——
FY2014—$24M$8M$5M——
FY2013—$48M$10M$2M——
FY2012—$33M$0$1M——
FY2011—$48M—$3M——
FY2010—$7M—$4M—$4M

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 17, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearSLSS&P 500
2019−93.0%+31.5%
2020+35.1%+18.4%
2021−4.8%+28.7%
2022−57.3%−18.1%
2023−55.1%+26.3%
2024−1.9%+25.0%
2025+262.5%+17.9%
2026 to date+294.2%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about SELLAS

Why did SELLAS stock rise on Nov 17, 2026?
SELLAS said its Phase 3 REGAL trial of galinpepimut-S, a vaccine meant to keep acute myeloid leukemia from returning, met its main goal: patients lived a median 24.0 months, against 14.7 months on the doctors' choice of other treatment. The shares closed up about 156% at $19.15; these are company-reported topline results, the detailed analyses are still pending, and SELLAS has not yet applied for FDA approval. After the close, it filed to sell $150 million of new stock. Read the article →